Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Phillip John L'Huillier
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 61
- Beta
- 0.74
- Country
- GB
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -12.10
Financials
Revenue
$0.00-100.0%Net Income
$-5.75MEBITDA
$-5.46MFree Cash Flow
$-7.09MEPS (diluted)
$-0.01Shares Outstanding (diluted)
1.20B+637.2%Operating Expenses
$8.52MCash & Debt
$8.58MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $4.71M | $-12.27M | $-0.01 |
| 2024 | $5.27M | $-11.94M | $-0.01 |
| 2023 | $5.27M | $-11.94M | $-0.01 |
| 2022 | $0.00 | $-2.06M | $-0.01 |
| 2021 | $0.00 | $-15.48M | $-0.02 |
| 2020 | $0.00 | $-5.51M | $-0.01 |
| 2019 | $0.00 | $-5.63M | $-0.01 |
| 2018 | $0.00 | $-4.19M | $-0.01 |
| 2017 | $0.00 | $-3.54M | $-0.01 |
| 2016 | $0.00 | $-2.58M | $-0.01 |
| 2015 | $0.00 | $-2.41M | $-0.01 |
| 2014 | $0.00 | $-2.22M | $-0.01 |
| 2013 | $0.00 | $-1.90M | $-0.01 |
| 2012 | $0.00 | $557.1K | $0.00 |
Valuation
SCNLFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+66.67%Social Signal Score
Mentions (3)
- Newsproactiveinvestors.com·5h ago·Neutral
Scancell revs up for Nasdaq listing as cancer vaccine developer prepares phase III melanoma trial Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the developer of cancer immunotherapies, is pressing ahead with plans to list on the Nasdaq stock exchange following an all-share merger with US biotech Neuphoria Therapeutics, announced in July. The combined company will trade under the ticker "SCLT" and retain the Scancell name, with shareholders voting on the deal at a general meeting on 20 Oc…
View source ↗ - Newsproactiveinvestors.com·15d ago·Negative
Scancell Holdings secures $25m financing as it advances melanoma trial Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) told investors it has secured up to US$25 million of debt financing from funds and accounts managed by BlackRock, bolstering the funding package for the registrational Phase 3 trial of its lead melanoma treatment iSCIB1+. The company plans to draw an initial US$7 million following shareholder approval, with a further US$8 million expected to become available after completio…
View source ↗ - Newsproactiveinvestors.co.uk·51d ago·Negative
Scancell secures UK clearance for late-stage melanoma trial Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP), the cancer immunotherapy developer, has won UK regulatory approval to run a late-stage trial of its lead drug in advanced melanoma. The Medicines and Healthcare products Regulatory Agency (MHRA) has granted a clinical trial authorisation for the phase III registrational study of iSCIB1+.
View source ↗
Earnings
Fri, Oct 23(in 2 weeks)
Estimates and results for SCNLF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in SCNLF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.